Portrazza

Active Ingredient(s): Necitumumab
FDA Approved: * November 24, 2015
Pharm Company: * ELI LILLY CO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Portrazza Overview

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-sma...

Read more Portrazza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Necitumumab

Recent Portrazza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Necitumumab
  • Injection: 800mg/50ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Portrazza: (1 result)

Sorted by National Drug Code
  • 0002-7716 Portrazza 16 mg/ml Intravenous Solution by Eli Lilly and Company

Other drugs which contain Necitumumab or a similar ingredient: (1 result)